全文获取类型
收费全文 | 89115篇 |
免费 | 7360篇 |
国内免费 | 3492篇 |
专业分类
耳鼻咽喉 | 818篇 |
儿科学 | 1947篇 |
妇产科学 | 1612篇 |
基础医学 | 9905篇 |
口腔科学 | 1820篇 |
临床医学 | 7768篇 |
内科学 | 9913篇 |
皮肤病学 | 1300篇 |
神经病学 | 3592篇 |
特种医学 | 4048篇 |
外国民族医学 | 62篇 |
外科学 | 10793篇 |
综合类 | 15128篇 |
现状与发展 | 22篇 |
预防医学 | 2800篇 |
眼科学 | 1151篇 |
药学 | 8677篇 |
55篇 | |
中国医学 | 3533篇 |
肿瘤学 | 15023篇 |
出版年
2024年 | 66篇 |
2023年 | 1198篇 |
2022年 | 1943篇 |
2021年 | 3375篇 |
2020年 | 3084篇 |
2019年 | 2576篇 |
2018年 | 2412篇 |
2017年 | 2998篇 |
2016年 | 3281篇 |
2015年 | 3455篇 |
2014年 | 5882篇 |
2013年 | 6837篇 |
2012年 | 5953篇 |
2011年 | 6211篇 |
2010年 | 5082篇 |
2009年 | 4857篇 |
2008年 | 4731篇 |
2007年 | 4591篇 |
2006年 | 4067篇 |
2005年 | 3690篇 |
2004年 | 3147篇 |
2003年 | 2577篇 |
2002年 | 2328篇 |
2001年 | 2077篇 |
2000年 | 1722篇 |
1999年 | 1523篇 |
1998年 | 1248篇 |
1997年 | 1153篇 |
1996年 | 984篇 |
1995年 | 981篇 |
1994年 | 846篇 |
1993年 | 644篇 |
1992年 | 530篇 |
1991年 | 456篇 |
1990年 | 378篇 |
1989年 | 321篇 |
1988年 | 324篇 |
1987年 | 255篇 |
1986年 | 207篇 |
1985年 | 309篇 |
1984年 | 298篇 |
1983年 | 212篇 |
1982年 | 261篇 |
1981年 | 199篇 |
1980年 | 162篇 |
1979年 | 145篇 |
1978年 | 109篇 |
1977年 | 78篇 |
1976年 | 69篇 |
1975年 | 44篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Biaoming Xu Yu Chen Mingjing Peng Jin Hai Zheng Chaohui Zuo 《International journal of cancer. Journal international du cancer》2023,152(2):110-122
Pancreatic cancer (PC) is a cancer of the digestive system, and pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of all PC cases. Exosomes derived from PDAC (PDAC-exosomes) promote PDAC development and metastasis. Exosomes are nanoscale vesicles secreted by most cells, which can carry biologically active molecules and mediate communication and cargo transportation among cells. Recent studies have focused on transforming exosomes into good drug delivery systems (DDSs) to improve the clinical treatment of PDAC. This review considers PDAC as the main research object to introduce the role of PDAC-exosomes in PDAC development and metastasis. This review focuses on the following two themes: (a) the great potential of PDAC-exosomes as new diagnostic markers for PDAC, and (b) the transformation of exosomes into potential DDSs. 相似文献
5.
《Vaccine》2022,40(19):2679-2695
Vaccinations are essential for preventing infectious diseases in children with chronic diseases as they have increased risk of infection from frequent use of biologics. Response to immunizations in this group is not well known.ObjectiveA systematic review was performed to evaluate three primary outcomes: efficacy; immunogenicity; and safety of vaccines in children with chronic conditions treated with biologics.MethodsThe protocol for our systematic review and meta-analysis was registered and published with PROSPERO. We searched electronic bibliographic databases for studies published from 2009 to 2019, focusing on vaccinations in children with chronic conditions treated with biologics.ResultsWe retrieved 532 records. Thirty-one full-text articles were selected, and 14 were included in the meta-analysis. No significant publication bias was found. Efficacy: limited data are available regarding the efficacy of vaccination, as most studies have focused on immunogenicity as surrogate outcome for efficacy. Immunogenicity: patients receiving anti-TNF-alpha therapy had a statistically significant risk of poor seroconversion (p = 0.028) and seroprotection by the serotype B influenza vaccine [inflammatory bowel disease (IBD) p = 0.013; juvenile idiopathic arthritis (JIA) p = 0.004]. We found adequate responses with H1N1 and H3N2 serotypes. Few studies existed for pneumococcal, hepatitis A virus, hepatitis B virus, varicella-zoster virus, Measles Mumps Rubella virus, and multiple vaccine administration. Safety: vaccine administration was not associated with serious side effects, but JIA patients on anti-TNF alpha therapy had a statistically significant risk of presenting with myalgia or arthralgia postinfluenza vaccine (p = 0.014).ConclusionsMore evidence concerning efficacy, immunogenicity, and safety of vaccinations is needed to guide physicians in the vaccine decision process for this pediatric population. 相似文献
6.
7.
《Journal of endodontics》2022,48(2):208-212.e3
IntroductionDiabetes mellitus (DM) is a complex multisystemic disorder that affects an estimated 21 million Americans. No studies have evaluated the association of DM with the prevalence of each pulpal diagnosis. The objective of this study was to compare the prevalence of each pulp diagnosis including symptomatic irreversible pulpitis (SIP), asymptomatic irreversible pulpitis, reversible pulpitis, normal pulp, and pulp necrosis (PN) in DM patients against a nondiabetic control group.MethodsA retrospective chart review was approved by Rutgers University Institutional Review Board. The prevalence of the diagnoses SIP, asymptomatic irreversible pulpitis, reversible pulpitis, normal pulp, and PN was calculated from AxiUm (Exan software, Las Vegas, NV) electronic health records at Rutgers School of Dental Medicine. The chi-square test was used to see the relationship between the 2 categoric variables. Second, binary logistic regression analyses were performed for each group.ResultsA total of 2979 teeth were diagnosed with a pulp condition between April 2013 and November 2018. The total tooth number of DM patients was 682, whereas the tooth number of nondiabetic patients was 2297. In the subgroup of patients younger than 40 years old, SIP was notably more prevalent in DM patients. In addition, the prevalence of PN in elderly DM patients (60–69 years old) was significantly higher than in the control group.ConclusionsThe prevalence of SIP in DM patients was significantly higher compared with the control group (<40 years old), suggesting the possibility that DM could hypersensitize the subgroup of patients younger than 40 years old to pulpitis pain. 相似文献
8.
9.
目的 观察超声引导下关节腔内注射重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(益赛普)治疗血友病性关节病(HA)的价值。方法 回顾性分析32例接受超声引导下穿刺关节腔注射益赛普的HA患者,对比观察治疗前及治疗后1个月血友病关节健康评分(HJHS)、视觉模拟评分(VAS),以及超声所示目标关节增生滑膜厚度、血流信号、Melchiorre及中国早期血友病性关节病超声检测(HEAD-US-C)评分,评估其治疗价值。结果 对32例均成功完成超声引导下穿刺关节腔及腔内注射益赛普,共对18例膝关节、7例肘关节及7例踝关节进行治疗。术后未出现感染、出血等并发症。治疗后1个月,目标关节HJHS、VAS、Melchiorre评分、HEAD-US-C评分及增生滑膜最大厚度、平均厚度、血流信号均低于治疗前(P均<0.01)。结论 超声引导下关节腔内注射益赛普治疗HA安全、有效。 相似文献
10.
《Journal of vascular and interventional radiology : JVIR》2022,33(10):1213-1221.e5
PurposeTo investigate the pharmacokinetics (PK) and early effects of conventional transarterial chemoembolization (TACE) using sorafenib and doxorubicin on tumor necrosis, hypoxia markers, and angiogenesis in a rabbit VX2 liver tumor model.Materials and MethodsVX2 tumor-laden New Zealand White rabbits (N = 16) were divided into 2 groups: 1 group was treated with hepatic arterial administration of ethiodized oil and doxorubicin emulsion (DOX-TACE), and the other group was treated with ethiodized oil, sorafenib, and doxorubicin emulsion (SORA-DOX-TACE). Animals were killed within 3 days of the procedure. Levels of sorafenib and doxorubicin were measured in blood, tumor, and adjacent liver using mass spectrometry. Tumor necrosis was determined by histopathological examination. Intratumoral hypoxia-inducible factor (HIF) 1α, vascular endothelial growth factor (VEGF), and microvessel density (MVD) were determined by immunohistochemistry.ResultsThe median intratumoral concentration of sorafenib in the SORA-DOX-TACE group was 17.7 μg/mL (interquartile range [IQR], 7.42–33.5 μg/mL), and its maximal plasma concentration (Cmax) was 0.164 μg/mL (IQR, 0.0798–0.528 μg/mL). The intratumoral concentration and Cmax of doxorubicin were similar between the groups: 4.08 μg/mL (IQR, 3.18–4.79 μg/mL) and 0.677 μg/mL (IQR, 0.315–1.23 μg/mL), respectively, in the DOX-TACE group and 1.68 μg/mL (IQR, 0.795–4.08 μg/mL) and 0.298 μg/mL (IQR, 0.241–0.64 μg/mL), respectively, in the SORA-DOX-TACE group. HIF-1α expression was increased in the SORA-DOX-TACE group than in the DOX-TACE group. Tumor volume, tumor necrosis, VEGF expression, and MVD were similar between the 2 groups.ConclusionsThe addition of sorafenib to DOX-TACE delivered to VX2 liver tumors resulted in high intratumoral and low systemic concentrations of sorafenib without altering the PK of doxorubicin. 相似文献